MedTrace Logo

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management

NCT01908075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 194723

Last updated 2013-07-25

No results posted yet for this study

Summary

To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.

Conditions

Interventions

DRUG

FP/SAL

DRUG

BDP/FOR

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Principal Investigators

  • David Price · University of Aberdeen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01908075 on ClinicalTrials.gov